Skip to main content
Terug
Watch Compare

Oncology Institute, Inc.

Datakwaliteit: 100%
Ook genoteerd als DFPH Nasdaq TOIIW Nasdaq
TOI
Nasdaq Services Health Services
€ 3,08
▼ € 0,03 (-0,96%)
Marktkapitalisatie: 303,44 M
Prijs
€ 3,07
Marktkapitalisatie
303,44 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 25,45% annually over 5 years — strong growth
Negative free cash flow of -27,79 M
Capital efficient — spends only 0,64% of revenue on capex

Groei

Revenue Growth (5Y)
25,45%
Boven sectorgemiddelde (3,76%)
Revenue (1Y)27,79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-29,53%
Net Margin-12,06%
Op. Margin-7,18%

Veiligheid

Debt / Equity
N/A
Current Ratio1,68
Interest Coverage-3,20

Waardering

PE (TTM)
-5,01
Onder sectorgemiddelde (-1,17)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (502 peers)
Metriek Aandeel Sector Mediaan
P/E -5,0 -1,2
P/B — 1,4
ROE % — -16,0
Net Margin % -12,1 -19,4
Rev Growth 5Y % 25,5 3,8
D/E — 0,4

ETFs Holding This Stock

GISMX GISMX
0,04% weight
GMSMX GMSMX
0,04% weight
GSMRX GSMRX
0,04% weight
IRSIX IRSIX
0,01% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight
VVICX VVICX
0,01% weight
IRSSX IRSSX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 27,79% Revenue Growth (3Y) 24,52%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 25,45% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 502,73 M Net Income (TTM) -60,61 M
ROE N/A ROA -37,48%
Gross Margin N/A Operating Margin -7,18%
Net Margin -12,06% Free Cash Flow (TTM) -27,79 M
ROIC -29,53% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,68
Interest Coverage -3,20 Asset Turnover 3,11
Working Capital 44,51 M Tangible Book Value -31,24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,01 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,60
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -9,16%
Market Cap 303,44 M Enterprise Value 379,63 M
Per Share
EPS (Diluted TTM) -0,54 Revenue / Share 5,09
FCF / Share -0,28 OCF / Share -0,25
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,64% FCF Conversion 45,85%
SBC-Adj. FCF -33,41 M Growth Momentum 2,34

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 502,73 M 393,41 M 324,24 M 252,48 M 203,00 M
Net Income -60,61 M -64,66 M -83,07 M 152.000,0 -10,93 M
EPS (Diluted) -0,54 -0,71 -0,92 -0,21 -0,16
Gross Profit — — — — —
Operating Income -36,08 M -60,12 M -77,02 M -81,95 M -45,86 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses 105,57 M 107,83 M 113,85 M 119,69 M 83,37 M
D&A 6,94 M 6,29 M 5,87 M 4,41 M 3,34 M
Interest Expense 11,28 M 7,50 M -6,78 M -4,08 M 320.000,0
Income Tax -131.000,0 0,0 -36.000,0 -243.000,0 -671.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 164,66 M 172,72 M 209,24 M 261,67 M 203,44 M
Total Liabilities 180,38 M 169,13 M 152,22 M 138,49 M 99,28 M
Shareholders' Equity -15,72 M 3,59 M 57,03 M 123,18 M 104,16 M
Total Debt 77,40 M 93,13 M 86,83 M 80,62 M 0,0
Cash & Equivalents — — — — —
Current Assets 112,75 M 112,42 M 143,49 M 130,42 M 154,06 M
Current Liabilities 70,96 M 52,22 M 34,79 M 29,72 M 29,80 M